{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T08:09:05Z","timestamp":1773734945327,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Berta-Ottenstein-Programme for Clinician Scientists"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Effective SARS-CoV-2 vaccination in patients receiving treatment with B-cell depleting agents is challenging. Information on vaccination responses in these patients are a valuable tool to develop efficient vaccination regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-center retrospective observational study, we report the humoral and cellular response in 34 patients receiving anti-CD20 antibody treatment for renal immune disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After base immunization with SARS-CoV-2-vaccines, 92.0% developed a cellular, 32.4% a humoral response. Humoral immunity correlated with B-cell counts and the timespan between anti-CD20 antibody treatment and vaccination. All patients with\u2009&gt;\u200921\/\u00b5l B-cells, or\u2009&gt;\u2009197\u00a0days after treatment showed humoral response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Adequate timing of SARS-CoV-2-vaccinations after anti-CD20 antibody treatment and CD19 measurements are crucial to generate immunity. Awaiting partial B-cell recovery by postponing regularly scheduled anti-CD20 treatment should be considered in patients with stable immune disease.<\/jats:p>\n                <jats:p><jats:italic>Trial registration:<\/jats:italic> This study has been retrospectively registered in the German Clinical Trials Register (DRKS00027049) on 29\/10\/2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07722-7","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T11:03:03Z","timestamp":1663153383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Frederic","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Huzly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakup","family":"Tanriver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"1","key":"7722_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0974-777X.77299","volume":"3","author":"AS Clem","year":"2011","unstructured":"Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73\u20138.","journal-title":"J Glob Infect Dis"},{"issue":"3","key":"7722_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100040","volume":"1","author":"MS Suthar","year":"2020","unstructured":"Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, Vanderheiden A, Nyhoff L, Davis CW, Adekunle O. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3): 100040.","journal-title":"Cell Rep Med"},{"issue":"1","key":"7722_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21609-2","volume":"12","author":"F Bertoglio","year":"2021","unstructured":"Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, Heine PA, Ballmann R, Schneider K-T, Roth KDR. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12(1):1\u201315.","journal-title":"Nat Commun"},{"key":"7722_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27105","author":"EH Akama-Garren","year":"2021","unstructured":"Akama-Garren EH, Li JX. Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: a retrospective study of 835 patients. J Med Virol. 2021. https:\/\/doi.org\/10.1002\/jmv.27105.","journal-title":"J Med Virol"},{"issue":"23","key":"7722_CR5","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291\u20133.","journal-title":"N Engl J Med"},{"issue":"11","key":"7722_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3949\/ccjm.87a.20056","volume":"87","author":"AL Day","year":"2020","unstructured":"Day AL, Winthrop KL, Curtis JR. The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. Cleve Clin J Med. 2020;87(11):695\u2013703.","journal-title":"Cleve Clin J Med"},{"key":"7722_CR7","doi-asserted-by":"crossref","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, El-Qunni AA, Haile A, Huang K, Kinnett B: Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Annals of internal medicine 2021.","DOI":"10.7326\/M21-1757"},{"key":"7722_CR8","doi-asserted-by":"crossref","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"7722_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/14760584.2014.874950","volume":"13","author":"R Mathew","year":"2014","unstructured":"Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines. 2014;13(2):285\u201398.","journal-title":"Expert Rev Vaccines"},{"key":"7722_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2022.105098","volume":"148","author":"D Huzly","year":"2022","unstructured":"Huzly D, Panning M, Smely F, Enders M, Komp J, Falcone V, Steinmann D. Accuracy and real life performance of a novel interferon-\u03b3 release assay for the detection of SARS-CoV2 specific T cell response. J Clin Virol. 2022;148: 105098.","journal-title":"J Clin Virol"},{"issue":"19","key":"7722_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380.","journal-title":"N Engl J Med"},{"issue":"9","key":"7722_CR12","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/rheumatology\/kew232","volume":"55","author":"FA Pearce","year":"2016","unstructured":"Pearce FA, Lanyon PC, Grainge MJ, Shaunak R, Mahr A, Hubbard RB, Watts RA. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology (Oxford). 2016;55(9):1656\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"7722_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat Med. 2021;27(9):1525\u20139.","journal-title":"Nat Med"},{"key":"7722_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220604","author":"R Spiera","year":"2021","unstructured":"Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220604.","journal-title":"Ann Rheum Dis"},{"key":"7722_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/art.42034","author":"S Jinich","year":"2021","unstructured":"Jinich S, Schultz K, Jannat-Khah D, Spiera R. B-cell reconstitution is strongly associated with COVID-19 vaccine responsiveness in rheumatic disease patients treated with rituximab. Arthritis Rheumatol. 2021. https:\/\/doi.org\/10.1002\/art.42034.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"7722_CR16","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","volume":"3","author":"MB Moor","year":"2021","unstructured":"Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, M\u00f6ller B, Njue LM, Medri C, Angelillo-Scherrer A, Borradori L. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789\u201397.","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"7722_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","volume":"80","author":"D Mrak","year":"2021","unstructured":"Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345\u201350.","journal-title":"Ann Rheum Dis"},{"key":"7722_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/art.42060","author":"AL Stefanski","year":"2021","unstructured":"Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Jahrsd\u00f6rfer B, Schrezenmeier H, Ludwig C, Sattler A. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis Rheumatol. 2021. https:\/\/doi.org\/10.1002\/art.42060.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"7722_CR19","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","volume":"4","author":"I Jyssum","year":"2021","unstructured":"Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, J\u00f8rgensen KK, Jahnsen J, Kro GB, Warren DJ. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2021;4(3):e177\u201387.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"7722_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/art.42058","volume":"74","author":"S Bitoun","year":"2022","unstructured":"Bitoun S, Henry J, Desjardins D, Vauloup-Fellous C, Dib N, Belkhir R, Mouna L, Joly C, Bitu M, Ly B. Rituximab Impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol. 2022;74(6):927\u201333.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"7722_CR21","doi-asserted-by":"publisher","first-page":"e2211497","DOI":"10.1001\/jamanetworkopen.2022.11497","volume":"5","author":"A Tolf","year":"2022","unstructured":"Tolf A, Wiberg A, M\u00fcller M, Nazir FH, Pavlovic I, Laur\u00e9n I, Mangsbo S, Burman J. Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated With Rituximab. JAMA Netw Open. 2022;5(5):e2211497\u2013e2211497.","journal-title":"JAMA Netw Open"},{"key":"7722_CR22","doi-asserted-by":"publisher","unstructured":"Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T, Provstgaard-Morys S, Clutterbuck E, Ramasamy MN, Aley PK, Farooq Mujadidi Y: Safety and immunogenicity report from the com-COV study\u2013a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. 2021.\nhttps:\/\/doi.org\/10.1016\/S0140-6736(21)01694-9","DOI":"10.1016\/S0140-6736(21)01694-9"},{"key":"7722_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01420-3","author":"AM Borobia","year":"2021","unstructured":"Borobia AM, Carcas AJ, P\u00e9rez Olmeda MT, Casta\u00f1o L, Jes\u00fas Bertr\u00e1n M, Garc\u00eda-P\u00e9rez J, Campins M, Portol\u00e9s A, Gonzalez-Perez M, Garc\u00eda Morales MT. Reactogenicity and immunogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1s: initial results of a randomised, adaptive, phase 2 trial (CombiVacS). Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)01420-3.","journal-title":"Lancet"},{"issue":"11","key":"7722_CR24","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","volume":"9","author":"D Hillus","year":"2021","unstructured":"Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert LJ, Tscheak P. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9(11):1255\u201365.","journal-title":"Lancet Respir Med"},{"key":"7722_CR25","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0003512021","author":"T Kolb","year":"2021","unstructured":"Kolb T, Fischer S, M\u00fcller L, L\u00fcbke N, Hillebrandt J, Andr\u00e9e M, Schmitz M, Schmidt C, K\u00fcc\u00fckk\u00f6yl\u00fc S, Koster L. Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients. Kidney360. 2021. https:\/\/doi.org\/10.34067\/KID.0003512021.","journal-title":"Kidney360"},{"issue":"4","key":"7722_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/TP.0000000000003983","volume":"106","author":"JSF Sanders","year":"2022","unstructured":"Sanders JSF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Fr\u00f6lke SC, Geers D, GeurtsvanKessel CH. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821\u201334.","journal-title":"Transplantation"},{"key":"7722_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927","author":"A Jena","year":"2021","unstructured":"Jena A, Mishra S, Deepak P, Kumar MP, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2021. https:\/\/doi.org\/10.1016\/j.autrev.2021.102927.","journal-title":"Autoimmun Rev"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07722-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07722-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07722-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T13:31:21Z","timestamp":1664976681000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07722-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7722"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07722-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is in conformity with the Helsinki and Istanbul declarations and its amendments. The study was approved by the local ethics committee (21-1580). Informed consent was waived due to the retrospective character of this study. The study was registered in the German Clinical Trials Register (DRKS00027049) on 29\/10\/2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. The results presented in this paper have not been published previously in whole or part.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"734"}}